Reciprocal mutations of neuropeptide Y receptor Y2 in human and chicken identify amino acids important for antagonist binding

被引:19
作者
Berglund, MM [1 ]
Fredriksson, R [1 ]
Salaneck, E [1 ]
Larhammar, D [1 ]
机构
[1] Uppsala Univ, Dept Neurosci, SE-75224 Uppsala, Sweden
关键词
site-directed mutagenesis; neuropeptide Y; peptide YY; G-protein-coupled receptor; modeling;
D O I
10.1016/S0014-5793(02)02534-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neuropeptide Y (NPY) receptor Y2 antagonist BIIE0246 has sub-nanomolar affinity for the human Y2 (hY2) receptor but binds very poorly to chicken Y2 (chY2) with micromolar affinity. Sequence comparisons identified several amino acids for investigation by mutagenesis. Reciprocal mutagenesis between hY2 and chY2 revealed that three of these, individually and in combination, are important for BIIE0246 binding, namely positions Gln(135) in transmembrane (TM) 3, Len(227) in TM5, and Leu(284) in TM6. Mutagenesis of hY2 to the corresponding amino in chY2 (generating hY2[Q135H,L227Q, L284F]) made the affinity of BIIE0246 as low as for chY2. Introduction into chY2 of the three human residues resulted in antagonist affinity almost as high as for hY2. To distinguish between direct and indirect effects, each of the three residues in hY2 was replaced with alanine. BIIE0246 bound with 28-fold lower affinity to hY2[L227A], suggesting the Leu(227) interacts directly with the antagonist. The other two alanine mutants bound with unaltered affinity, suggesting that the corresponding chY2 residues abolish binding through steric hindrance or charge repulsion. Thus, three amino acid residues can in an additive manner completely account for the difference in antagonist binding between the hY2 and chY2 receptors. These results will be useful for construction of three-dimensional models of the widely divergent NPY receptor subtypes. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:5 / 9
页数:5
相关论文
共 26 条
[1]   Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene [J].
Ammar, DA ;
Eadie, DM ;
Wong, DJ ;
Ma, YY ;
Kolakowski, LF ;
YangFeng, TL ;
Thompson, DA .
GENOMICS, 1996, 38 (03) :392-398
[2]   Binding properties of three neuropeptide Y receptor subtypes from zebrafish: Comparison with mammalian Y1 receptors [J].
Berglund, MM ;
Lundell, I ;
Cabrele, C ;
Serradeil-Le Gal, C ;
Beck-Sickinger, AG ;
Larhammar, D .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (12) :1815-1822
[3]   Y-receptor subtypes - How many more? [J].
Blomqvist, AG ;
Herzog, H .
TRENDS IN NEUROSCIENCES, 1997, 20 (07) :294-298
[4]   BIIE0246:: A selective and high affinity neuropeptide YY2 receptor antagonist [J].
Doods, H ;
Gaida, W ;
Wieland, HA ;
Dollinger, H ;
Schnorrenberg, G ;
Esser, F ;
Engel, W ;
Eberlein, W ;
Rudolf, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 384 (2-3) :R3-R5
[5]   Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites [J].
Du, P ;
Salon, JA ;
Tamm, JA ;
Hou, CF ;
Cui, WL ;
Walker, MW ;
Adham, N ;
Dhanoa, DS ;
Islam, I ;
Vaysse, PJJ ;
Dowling, B ;
Shifman, Y ;
Boyle, N ;
Rueger, H ;
Schmidlin, T ;
Yamaguchi, Y ;
Branchek, TA ;
Weinshank, RL ;
Gluchowski, C .
PROTEIN ENGINEERING, 1997, 10 (02) :109-117
[6]  
Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7
[7]  
Gehlert DR, 1996, MOL PHARMACOL, V49, P224
[8]   EXPRESSION CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF A HUMAN HIPPOCAMPAL NEUROPEPTIDE-Y PEPTIDE YY Y2 RECEPTOR SUBTYPE [J].
GERALD, C ;
WALKER, MW ;
VAYSSE, PJJ ;
HE, CG ;
BRANCHEK, TA ;
WEINSHANK, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) :26758-26761
[9]   Neuropeptide Y phase shifts circadian rhythms in vivo via a Y-2 receptor [J].
Huhman, KL ;
Gillespie, CF ;
Marvel, CL ;
Albers, HE .
NEUROREPORT, 1996, 7 (07) :1249-1252
[10]   Different binding sites for the neuropeptide YY1 antagonists 1229U91 and J-104870 on human Y1 receptors [J].
Kanno, T ;
Kanatani, A ;
Keen, SLC ;
Arai-Otsuki, S ;
Haga, Y ;
Iwama, T ;
Ishihara, A ;
Sakuraba, A ;
Iwaasa, H ;
Hirose, M ;
Morishima, H ;
Fukami, T ;
Ihara, M .
PEPTIDES, 2001, 22 (03) :405-413